Kontour (Xi'an) Medical Technology Co., Ltd. (SHA:688314)
China · Delayed Price · Currency is CNY 43.03
+0.12 (0.28%)
Apr 30, 2026, 2:34 PM CST
SHA:688314 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 341.87 | 311.71 | 262.63 | 229.61 | 206.31 |
Other Revenue | 9.2 | 10.23 | 12.4 | 10.34 | 6.24 |
| 351.08 | 321.95 | 275.03 | 239.95 | 212.55 | |
Revenue Growth (YoY) | 9.05% | 17.06% | 14.62% | 12.89% | 29.54% |
Cost of Revenue | 76.79 | 67.93 | 60.38 | 50.19 | 41.99 |
Gross Profit | 274.28 | 254.01 | 214.65 | 189.76 | 170.56 |
Selling, General & Admin | 121.19 | 119.76 | 107.33 | 91.58 | 75.18 |
Research & Development | 25.64 | 23.9 | 17.64 | 18.3 | 16.8 |
Other Operating Expenses | 4.58 | 4.64 | 4.42 | 4.03 | 2.77 |
Operating Expenses | 152.02 | 147.96 | 129.38 | 114.11 | 94.71 |
Operating Income | 122.26 | 106.05 | 85.26 | 75.64 | 75.85 |
Interest Expense | -2.32 | -2.17 | -1.89 | -1.23 | -0.74 |
Interest & Investment Income | 2.03 | 5.22 | 5.2 | 8.14 | 4.85 |
Currency Exchange Gain (Loss) | 0.15 | -0.37 | 0.23 | 0.49 | 0.03 |
Other Non Operating Income (Expenses) | -0.72 | -1.75 | -0.3 | -0.2 | -0.17 |
EBT Excluding Unusual Items | 121.4 | 106.98 | 88.5 | 82.85 | 79.82 |
Impairment of Goodwill | -2.19 | - | - | - | - |
Gain (Loss) on Sale of Investments | -9.21 | -12.59 | -1.86 | - | - |
Gain (Loss) on Sale of Assets | -0.38 | 0.44 | -0.06 | -0 | 0.02 |
Asset Writedown | - | -1.87 | - | -0.04 | -0.35 |
Other Unusual Items | 5.89 | 13.04 | 5.18 | 5.66 | 15.9 |
Pretax Income | 115.52 | 106 | 91.75 | 88.46 | 95.39 |
Income Tax Expense | 17.77 | 18.37 | 17.28 | 14.3 | 14.21 |
Earnings From Continuing Operations | 97.75 | 87.64 | 74.47 | 74.16 | 81.18 |
Minority Interest in Earnings | 0.96 | 0.76 | 1.04 | 1.53 | 0.44 |
Net Income | 98.7 | 88.4 | 75.51 | 75.69 | 81.63 |
Net Income to Common | 98.7 | 88.4 | 75.51 | 75.69 | 81.63 |
Net Income Growth | 11.66% | 17.07% | -0.23% | -7.28% | 55.83% |
Shares Outstanding (Basic) | 82 | 81 | 81 | 81 | 73 |
Shares Outstanding (Diluted) | 82 | 81 | 81 | 81 | 73 |
Shares Change (YoY) | 0.58% | -0.12% | -0.23% | 11.81% | 19.10% |
EPS (Basic) | 1.21 | 1.09 | 0.93 | 0.93 | 1.12 |
EPS (Diluted) | 1.21 | 1.09 | 0.93 | 0.93 | 1.12 |
EPS Growth | 11.01% | 17.20% | - | -17.07% | 30.84% |
Free Cash Flow | 66.65 | 92.86 | 71 | 73.78 | 48.05 |
Free Cash Flow Per Share | 0.82 | 1.15 | 0.87 | 0.91 | 0.66 |
Dividend Per Share | 0.520 | 0.360 | 0.320 | 0.371 | 0.443 |
Dividend Growth | 44.44% | 12.50% | -13.84% | -16.14% | 19.25% |
Gross Margin | 78.13% | 78.90% | 78.05% | 79.08% | 80.25% |
Operating Margin | 34.83% | 32.94% | 31.00% | 31.52% | 35.69% |
Profit Margin | 28.12% | 27.46% | 27.46% | 31.54% | 38.40% |
Free Cash Flow Margin | 18.98% | 28.84% | 25.82% | 30.75% | 22.61% |
EBITDA | 135.15 | 117.56 | 95.62 | 85.56 | 83.02 |
EBITDA Margin | 38.50% | 36.52% | 34.77% | 35.66% | 39.06% |
D&A For EBITDA | 12.88 | 11.51 | 10.36 | 9.91 | 7.17 |
EBIT | 122.26 | 106.05 | 85.26 | 75.64 | 75.85 |
EBIT Margin | 34.83% | 32.94% | 31.00% | 31.52% | 35.69% |
Effective Tax Rate | 15.38% | 17.33% | 18.83% | 16.17% | 14.90% |
Revenue as Reported | 351.08 | 321.95 | 275.03 | 239.95 | 212.55 |
Advertising Expenses | 12.84 | 15.93 | 17.77 | 19.97 | 17.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.